The US Food and Drug Administration (FDA) recently approved lenacapavir, marketed as Yeztugo, as the first twice-yearly preexposure prophylaxis (PrEP) that reduces HIV risk.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *